GATINEAU, Quebec, March 06, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“Hydropothecary”) (TSX VENTURE:THCX) is pleased to announce a significant price reduction for one of its most popular and innovative products, Elixir THC. Clients can now purchase the country’s first sublingual peppermint oil cannabis mist for $69/15ml bottle.



Award-winning Elixir THC contains cannabis oil in a refreshing peppermint oil base that can be used under the tongue or mixed into food or drink. Hydropothecary credits improvements in its cannabis oil extraction processes for its decision to decrease the price of its Elixir THC spray from the original $89/15ml bottle, to the new $69/15ml bottle, a 22% reduction.

“Hydropothecary is dedicated to creating and producing the highest-quality innovative products that meet the daily needs of our customers, and are accessible to as many Canadians as possible,” said James McMillan, Hydropothecary’s Vice-President, Business Development. “I am very pleased to be able to pass these lower production costs for our oils and extractions on to our clients.”

Along with its refreshing base, Elixir THC contains close to the maximum allowable THC level of 30mg/ml for a cannabis oil under current Health Canada's Access to Cannabis for Medical Purposes Regulations. Packaged in a discrete, child-resistant spray bottle, Elixir THC provides an enjoyable experience for our customers while protecting the safety of children.

First launched in July 2017, Elixir THC has gained national recognition, winning a number of prestigious awards. They include third runner-up for Best New Cannabis Product and second runner-up for the Top High THC Oil prize at the 2017 Lift Canadian Cannabis Awards. Hydropothecary’s Elixir line of sublingual cannabis oil sprays was recently expanded to include the new Elixir CBD peppermint oil cannabis spray, continuing the company’s national reputation as an industry leader in product creativity and customer satisfaction.

About Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary creates award-winning innovative, easy to use and easy to understand products. Hydropothecary is rapidly increasing its production capacity in the lead-up to recreational adult-use cannabis. Expansion plans will result in a total of 1.3 million sq. ft. of production space, producing 108,000 kg of dried cannabis per year, making Hydropothecary one of the largest producers in the country. With industry-leading cash cost per gram of $0.89, Hydropothecary is the lowest cost producer in the country. The first licensed producer in Quebec, Hydropothecary is headquartered in the province.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Media Contact Information

Shawn Lyons

Manager, Media Relations and Strategic Communications

819-576-3637

shawn.lyons@thehydropothecary.com

Investor Relations Contact Information

Jennifer Smith

Manager of Financial Reporting and Investor Relations

1-866-438-THCX (8429)

invest@THCX.com

www.THCX.com

Director

Adam Miron

819-639-5498